Absolute Antibody
Private Company
Funding information not available
Overview
Founded in 2012 and based in Oxford, Absolute Antibody has established itself as a key provider of engineered recombinant antibody reagents and services. The company's core strength lies in its ability to produce antibodies in various formats (e.g., IgG, Fab, scFv) and species backbones, which are critical tools for preclinical research and therapeutic discovery. It operates primarily as a B2B service and reagent provider, catering to academic, biotech, and pharmaceutical clients globally. While not a traditional therapeutic developer, its technology enables and accelerates the pipelines of its partners.
Technology Platform
Recombinant antibody engineering and production platform utilizing mammalian expression systems for species engineering, antibody formatting (IgG, Fab, scFv, bispecifics), humanization, and recombinant reproduction of existing antibodies.
Opportunities
Risk Factors
Competitive Landscape
Absolute Antibody competes in the recombinant antibody segment against large, diversified life science tools companies like Bio-Techne, Abcam, and Sino Biological, as well as specialized CROs and service providers. Its differentiation lies in its deep focus on species engineering and flexible formatting, which addresses specific preclinical research needs not fully met by larger catalog-driven players.